by Peter Ciszewski | Jun 25, 2020
Jaap Groothoff, MD of the University of Amsterdam discusses his research on primary hyperoxaluria type 1 (PH1). PH1 is an ultra-rare, inherited disorder in which the body produces excess amounts of oxalate, which is normally filtered through the kidneys and...
by Peter Ciszewski | Jun 24, 2020
Othman Al-Sawaf, MD of the University Hospital of Cologne discusses how the results from the multicenter, open-label, randomized, phase 3 CLL14 clinical trial. As Dr. Al-Sawaf, explains in this video, the trial data showed significant improvement with...
by Peter Ciszewski | Jun 23, 2020
Kathleen Hawker, MD, Group Medical Director at Genentech, describes two abstracts presented at the European Academy of Neurology Congress (EAN 2020) showing the benefits of the drug satralizumab to treat adolescent and adult patients with neuromyelitis optica...
by Peter Ciszewski | Jun 22, 2020
Steve Noga, MD of Takeda Oncology discusses the results of the phase 3 TOURMALINE-MM4 clinical trial, evaluating ixazomib as maintenance therapy for multiple myeloma. The results of this study were recently published for the European Hematology Association...
by Peter Ciszewski | Jun 19, 2020
The US Food and Drug Administration (FDA) has approved Cyrstiva (burosumab) to treat patients with tumor-induced osteomalacia. TIO is a rare paraneoplastic condition commonly characterized by bone pain, muscle weakness and fractures. These tumors secrete excess...
